Valproic acid treatment in six patients with spinal muscular atrophy.
Tsai
L-K
LK
Yang
C-C
CC
Hwu
W-L
WL
Li
H
H
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D053580:Muscle Strength / Q000187:drug effects / Q000502:physiology; D018908:Muscle Weakness / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D009134:Muscular Atrophy, Spinal / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010349:Patient Compliance; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D015430:Weight Gain / Q000187:drug effects
D000927:Anticonvulsants; D014635:Valproic Acid